Get the Stockscreener App
1.71
2.29%
-0.04
After Hours:
1.69
-0.02
-1.17%
Biovie Inc stock is traded at $1.71, with a volume of 92,548.
It is down -2.29% in the last 24 hours and down -12.31% over the past month.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
See More
Previous Close:
$1.75
Open:
$1.8
24h Volume:
92,548
Relative Volume:
0.32
Market Cap:
$12.88M
Revenue:
-
Net Income/Loss:
$-25.56M
P/E Ratio:
-0.3288
EPS:
-5.2
Net Cash Flow:
$-19.35M
1W Performance:
-9.52%
1M Performance:
-12.31%
6M Performance:
+41.32%
1Y Performance:
-38.27%
1-Day Range:
$1.69
$1.80
1-Week Range:
$1.69
$1.92
52-Week Range:
$0.62
$9.56
Biovie Inc Stock (BIVI) Company Profile
Name
Biovie Inc
Sector
Industry
Phone
775-888-3162
Address
680 W NYE LANE, CARSON CITY
Compare BIVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIVI
Biovie Inc
|
1.71 | 13.19M | 0 | -25.56M | -19.35M | -5.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Biovie Inc Stock (BIVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-15-21 | Initiated | B. Riley Securities | Buy |
Biovie Inc Stock (BIVI) Latest News
Analyzing recovery setups for BioVie Inc. investorsLayoff News & Accurate Buy Signal Notifications - newser.com
Can BioVie Inc. stock beat analyst upgradesJuly 2025 PostEarnings & Reliable Momentum Entry Alerts - newser.com
Key metrics from BioVie Inc.’s quarterly dataPrice Action & Risk Managed Investment Signals - newser.com
Momentum divergence signals in BioVie Inc. chartQuarterly Investment Review & Reliable Breakout Forecasts - newser.com
Using data filters to optimize entry into BioVie Inc.Dip Buying & Short-Term Trading Alerts - newser.com
Chart based exit strategy for BioVie Inc.Buy Signal & Accurate Entry and Exit Point Alerts - newser.com
Identifying reversal signals in BioVie Inc.Fed Meeting & Safe Capital Investment Plans - newser.com
Can volume confirm reversal in BioVie Inc.Portfolio Update Summary & Stepwise Entry and Exit Trade Signals - newser.com
Using Ichimoku Cloud for BioVie Inc. technicalsOil Prices & Free Technical Pattern Based Buy Signals - newser.com
BioVie Inc Stock Analysis and ForecastStock Split Announcements & Affordable Stock Picks - earlytimes.in
Nexalin Technology and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Holland Sentinel
Is it time to cut losses on BioVie Inc.July 2025 Earnings & Reliable Volume Spike Alerts - newser.com
Is BioVie Inc. stock oversold or undervaluedMarket Growth Report & Weekly Top Gainers Alerts - fcp.pa.gov.br
BioVie Inc.’s NE3107: A Promising Study for Long COVID Relief - TipRanks
BioVie Inc.’s NE3107 Study: A New Hope for Early Parkinson’s Treatment - TipRanks
Is BioVie Inc. stock a safe haven asset2025 Year in Review & Safe Entry Momentum Stock Tips - fcp.pa.gov.br
Biovie Inc Stock (BIVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):